… randomized controlled trials and … influenza vaccine that has been proven superior (24.2%
greater efficacy: 95% confidence interval [CI] 9.7–36.5%) to standard-dose influenza vaccine in …

… partially explain the lower dose needed to trigger the immune response in this study compared
with the usual 15 μg per dose used in seasonal trivalent influenza vaccines, although the …

… influenza vaccine is more effective than standard-dose vaccine for prevention of
laboratory-confirmed influenza in … of high-dose versus standard-dose influenza vaccine in …

… The Centres for Disease Control and … single dose of the 2008/2009 formulation of intradermal
(ID) or intramuscular (IM) inactivated trivalent influenza vaccine as part of a previous phase …

… ), randomized, active-controlled phase II trial in adults 50–64 … at least one dose of study or
control vaccine. Results were … least one dose of study or control vaccine, received vaccine …

… Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose
and standard-dose influenza vaccine in adults 65 years of age and older. …

… influenza vaccines, representing an important development for pandemic preparedness. In
this phase 1/2 randomized, controlled, … vaccines produced at 2 separate manufacturing sites. …

… is recommended for people older than 65 years, the use of a placebo is now deemed to be
unethical in elderly people; the last placebo-controlled vaccine efficacy trial in this population …

… Finally, the current study evaluated only one formulation of the trivalent influenza vaccine
designed for a specific influenza season, and the OPA analyses were performed post hoc. …

… recently received trivalent seasonal influenza vaccination, compared with … influenza
vaccination, or intercurrent seasonal influenza on immune responses to pandemic influenza vaccine …